



PatBase Export

Created by: SIC10@patbase.com
Created on: 03 November 2022
Search: 6 AND 7

Records: 9 (1-9 of 9)
Export type: Family Export

Search History

Step	Search	Results
1	SiRNA	18,393
2	apolipoprotein(a) OR LPA gene	999
3	1 AND 2	46
4	3 AND PD<20181113	31
5	iRNA	766
6	Inhibit* OR supression	831,919
7	LPA near ("gene")	18
8	5 AND 7	0
9	5 AND 2	0
10	6 AND 7	9

1. Family 63599518 (US2016272970 AA)

[View in PatBase](#)

Title
[EN] RNA INTERFERENCE AGENTS

Abstract
[EN] Described are RNAi interference agents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to double stranded modified oligonucleotide molecules having blunt ends and a least one ribonucleotide near the 5' end of a sense strand capable of mediating RNA interference (RNAi) against target nucleic acid sequences. The RNAi agents are useful in the treatment of diseases or conditions that respond to inhibition of gene expression or activity in a cell, tissue, or organism.


International Class: A61K38/07; C07K5/10; C07K5/107; A61K48/00; A61P9/00; C12N15/113; A61K31/713; C07H19/00; C12N15/11; C12N15/87; C12Q1/68; C07K1/06; C07H19/20; C07H21/02; A61K47/48; A61P7/10; C12N15/63; A61K31/105; A61K31/40; C07D207/404; A61K47/64; A61K47/42; A61P7/02; A61K45/06; A61K47/54; A61P35/00; A61K31/7072; A61K31/7076; A61K31/7105; A61P43/00; C07H1/00; C07H19/067; C07H19/167; A61K47/60; A61K47/65; C07K5/103; C07H21/04; C07H5/06; A61K; C12N; C07K; A61K31/7088; A61P1/16; C07H; A61P31/20; C07H19/06; C07H19/10; C07H19/16; C07H19/207; A61K45/00; C07K14/47; C07D403/12; A61K31/7115; A61K31/7125; A61K47/56; A61K47/66; A61P3/00; A61P9/12; C07K5/02; C07K5/04; A61P13/12; A61P3/04; A61P3/06; A61P9/10; C12N5/071; C12N5/09; C07H23/00; A61K31/661; A61K47/22; A61K47/26; A61K47/51; A61K47/62; C07H15/04; A61K47/61; C12N15/88; C12N5/10; A61K31/712; A61P7/00; A61K38/00; C07H21/00; C12N15/00; A61K47/55; A61K47/50; A61K38/06; A61K31/7008; A61K31/711; A61K9/00; A61K31/7028; C07D245/04; A61K47/06; C07H15/18

Cooperative Patent Class: A61K31/713; A61K45/06; A61K47/548; A61K47/60; A61K47/64; A61P3/00; A61P35/00; A61P43/00; A61P9/00; A61P9/12; C12N15/113; C12N15/1135; C12N2310/14; C12N2310/315; C12N2310/321; C12N2310/322; C12N2310/343; C12N2310/346; C12N2310/351; C12N2310/3521; C12N2310/3533; C12N2320/30; C12N2320/31; C12N2320/32; A61K47/42; A61K47/554; A61K9/0019; A61P7/02; A61P7/10; C12N15/1137; C12N2310/3515; A61K38/00; A61K47/542; A61K47/549; A61K47/65; C07K5/1008; C07K5/101; C07K5/1016; A61K31/7088; A61P1/16; C12N2310/31; C12N2310/3517; C12Y304/21; A61P31/20; C07H19/06; C07H19/10; C07H19/16; C07H19/207; C07H21/00; C07H21/02; C12N2310/312; C12N2310/323; C12N2310/3231; C12N2310/3233; C12N2310/3519; A61K31/7008; A61K31/7105; A61K31/711; A61K47/555; C07H21/04; C07H5/06; C12N2310/317; C12N2310/32; C12N2310/332; A61K47/545; C12N15/111; C12N2320/50; A61K47/54; C07K1/06; C12N2310/344; A61K47/48123

US Class: 1/1; 514/21.9; 514/25; 514/44A; 536/24.5; 540/587

Family Information

Patent Number	Publication Date	Application Number	Application Date
AR104754 AA	20170809	AR2016P101525	20160527
AR106227 AA	20171227	AR2016P103006	20160930
AR108217 AA	20180801	AR2017P100567	20170307
AR121850 AB	20220713	AR2021P100996	20210415
AU2016233364 AA	20170921	AU20160233364	20160316
AU2016270593 AA	20171130	AU20160270593	20160527
AU2016270593 BB	20211118	AU20160270593	20160527
AU2016270597 AA	20171109	AU20160270597	20160527
AU2016270597 BB	20220526	AU20160270597	20160527
AU2016331084 AA	20180419	AU20160331084	20160930
AU2016331084 BB	20220908	AU20160331084	20160930
AU2017279512 AA	20181206	AU20170279512	20170606
AU2017279512 BB	20210819	AU20170279512	20170606
AU2017320582 AA	20190321	AU20170320582	20170307
AU2021266265 AA	20211209	AU20210266265	20211110
AU2022200865 AA	20220303	AU20220200865	20220210
AU2022203170 AA	20220602	AU20220203170	20220512
BR112017025698 A2	20180814	BR20171125698	20160527
BR112017025719 A2	20180807	BR20171125719	20160527
BR112018006489 A2	20181009	BR20181106489	20160930
BR112019004178 A2	20190528	BR20191104178	20170307
CA2979703 AA	20170913	CA20162979703	20160316



Patent Number	Publication Date	Application Number	Application Date
CA2984498 AA	20171030	CA20162984498	20160527
CA2984499 AA	20171030	CA20162984499	20160527
CA3000397 AA	20180328	CA20163000397	20160930
CA3011668 AA	20180716	CA20173011668	20170307
CA3023764 AA	20181108	CA20173023764	20170606
CL2018000803 A1	20180831	CL2018000803	20180328
CN107614002 A	20180119	CN201680031097	20160527
CN107614002 B	20220104	CN201680031097	20160527
CN107635550 A	20180126	CN201680016228	20160316
CN107635550 B	20211224	CN201680016228	20160316
CN108064156 A	20180522	CN201680031412	20160527
CN108064156 B	20220201	CN201680031412	20160527
CN108064313 A	20180522	CN201680027422	20160316
CN108064313 B	20210730	CN201680027422	20160316
CN108368506 A	20180803	CN201680057095	20160930
CN109462981 A	20190312	CN201780042047	20170307
CN109526222 A	20190326	CN201780034726	20170606
CN109526222 B	20220429	CN201780034726	20170606
CN113493789 A	20211012	CN202110788589	20160316
CN114601845 A	20220610	CN202210078884	20160527
CN114736256 A	20220712	CN202210360585	20170606
CO20180003678 A2	20181130	CO20180003678	20180405
CR20180231 A	20180531	CR20180000231	20160930
DE602016035891 D1	20200528	DE201660035891T	20160316
DE602016050702 D1	20210121	DE201660050702T	20160527
DE602016062858 D1	20210916	DE201660062858T	20160930
DK3356529 T3	20211108	DK20160852695T	20160930
EA036949 B1	20210119	EA20170092101	20160527
EA038478 B1	20210903	EA20180090864	20160930
EA201792101 A1	20180629	EA20170092101	20160527
EA201792103 A1	20180629	EA20170092103	20160527
EA201890864 A1	20180928	EA20180090864	20160930
EA201891423 A1	20191031	EA20180091423	20170307
EA201892285 A1	20190731	EA20180092285	20170606
EP3270903 A1	20180124	EP20160765618	20160316
EP3270903 A4	20181219	EP20160765618	20160316
EP3270903 B1	20200506	EP20160765618	20160316
EP3271482 A2	20180124	EP20160765632	20160316
EP3271482 A4	20190213	EP20160765632	20160316
EP3302503 A1	20180411	EP20160804086	20160527
EP3302503 A4	20190807	EP20160804086	20160527
EP3302516 A1	20180411	EP20160804090	20160527
EP3302516 A4	20190731	EP20160804090	20160527
EP3302516 B1	20201230	EP20160804090	20160527
EP3356529 A2	20180808	EP20160852695	20160930
EP3356529 A4	20190904	EP20160852695	20160930
EP3356529 B1	20210825	EP20160852695	20160930
EP3464313 A1	20190410	EP20170810836	20170606

Patent Number	Publication Date	Application Number	Application Date
EP3464313 A4	20200226	EP20170810836	20170606
EP3506913 A1	20190710	EP20170847109	20170307
EP3506913 A4	20200610	EP20170847109	20170307
EP4029941 A1	20220720	EP20210191363	20160930
ES2896298 T3	20220224	ES20160852695T	20160930
HK1252852 A1	20190606	HK20180112183	20180921
HK1259063 A1	20191122	HK20190101563	20190129
HK1259063 B	20220211	HK20190101563	20190129
HK40007072 A1	20200529	HK20190130541	20191008
HK40011750 A1	20200717	HK20206001264	20200110
HR20211410 T1	20211224	HR20210001410	20160930
HU055942 T2	20220128	HU20160852695T	20160930
ID201811363 A	20181019	ID2018PID02731	20160930
IL254518 A0	20171130	IL20160254518	20160316
IL255998 A0	20180131	IL20160255998	20160527
IL255999 A0	20180131	IL20160255999	20160527
IL258333 A0	20180531	IL20160258333	20160930
IL258333 A1	20220301	IL20160258333	20160930
IL263437 A0	20190131	IL20170263437	20170606
IL263437 A1	20220301	IL20170263437	20170606
IL264750 A0	20190430	IL20170264750	20170307
IL290566 AA	20220401	IL20160290566	20160930
IL290633 AA	20220401	IL20170290633	20170606
IN201727032835 A	20171103	IN201727032835	20170916
IN201727042275 A	20180216	IN201727042275	20171124
IN201727042483 A	20180420	IN201727042483	20171127
IN201817014635 A	20180907	IN201817014635	20180417
IN201827046205 A	20191129	IN201827046205	20181206
IN201927007924 A	20190802	IN201927007924	20190228
JP2018509913 T2	20180412	JP20170549311T	20160316
JP2018510164 T2	20180412	JP20170549325T	20160316
JP2018516595 T2	20180628	JP20180513740T	20160527
JP2018517769 T2	20180705	JP20180513741T	20160527
JP2018529732 T2	20181011	JP20180516738T	20160930
JP2019517588 T2	20190624	JP20190516096T	20170606
JP2019526527 T2	20190919	JP20180555750T	20170307
JP2021000102 A2	20210107	JP20200148172	20160316
JP2021087459 A2	20210610	JP20210039949	20160930
JP2022001576 A2	20220106	JP20210151282	20160527
JP2022028920 A2	20220216	JP20210196293	20170307
JP2022059052 A2	20220412	JP20220022652	20170606
JP2022113835 A2	20220804	JP20220096415	20160930
JP6773677 B2	20201021	JP20170549325T	20160316
JP6966427 B2	20211117	JP20180513741T	20160527
JP6989521 B2	20220105	JP20180555750T	20170307
JP6991966 B2	20220203	JP20180516738T	20160930
JP7021076 B2	20220216	JP20180513740T	20160527
JP7028865 B2	20220302	JP20190516096T	20170606

Patent Number	Publication Date	Application Number	Application Date
JP7116212 B2	20220809	JP20210039949	20160930
KR102403408 B1	20220530	KR20197004205	20170307
KR102426487 B1	20220727	KR20187034959	20170606
KR20180010235 A	20180130	KR20177036710	20160527
KR20180011198 A	20180131	KR20177036709	20160527
KR20180052703 A	20180518	KR20187010095	20160930
KR20190015277 A	20190213	KR20187034959	20170606
KR20190043132 A	20190425	KR20197004205	20170307
KR20220077157 A	20220608	KR20227017576	20170307
KR20220108204 A	20220802	KR20227025704	20170606
LT3356529 T	20211227	LT20160054729T	20160930
MA43347 A	20180808	MA20170043347	20170406
MA43347 B1	20211130	MA20170043347	20170406
MX2017011422 A1	20171110	MX20170011422	20160316
MX2017014638 A1	20180123	MX20170014638	20160527
MX2017014641 A1	20180123	MX20170014641	20160527
MX2018003833 A1	20180618	MX20180003833	20160930
MX2018009853 A1	20181109	MX20180009853	20170307
MX2018015109 A1	20190422	MX20180015109	20170606
MX382851 B	20210524	MX20170014638	20160527
PE11392018 A1	20180717	PE20180000487	20160930
PE20181139 A1	20180717	PE20180000487	20160930
PH2018500713 A	20181015	PH20180500713	20180328
PL3356529 T3	20211220	PL20160852695T	20160930
PT3356529 T	20211104	PT20160852695T	20160930
RS62523 B1	20211130	RS20210001351	20160930
SG10201912835Q A1	20200227	SG20191012835	20170307
SG10202008530T A1	20201029	SG20201008530	20160930
SG10202105989W A1	20210729	SG20211005989	20160527
SG11201708602X A1	20171228	SG20171108602	20160527
SG11201901841T A1	20190328	SG20191101841	20170307
SI3356529 T1	20220131	SI20160031374T	20160930
TN2018000094 A1	20190708	TN20180000094	20160930
TR2021017126 T4	20211122	TR20210017126T	20160930
TW201639962 A	20161116	TW20160108327	20160317
TW201642874 A	20161216	TW20160108329	20160317
TW201704471 A	20170201	TW20160108331	20160317
TW201705964 A	20170216	TW20160116759	20160527
TW201716426 A	20170516	TW20160116747	20160527
TW201726918 A	20170801	TW20160131823	20160930
TW201801748 A	20180116	TW20170118757	20170606
TW201811375 A	20180401	TW20170107455	20170307
TWI732761 B	20210711	TW20160116747	20160527
TWI761305 B	20220421	TW20160116759	20160527
TWI775743 B	20220901	TW20170107455	20170307
UA121998 C2	20200825	UA20180004593	20160930
US10005815 BB	20180626	US20160166323	20160527
US10047361 BB	20180814	US20170716809	20170927

Patent Number	Publication Date	Application Number	Application Date
US10294474 BB	20190521	US20170452324	20170307
US10308941 BB	20190604	US20170715765	20170926
US10662427 BB	20200526	US20180901810	20180221
US10858658 BB	20201208	US20190429501	20190603
US10927373 BB	20210223	US20180954316	20180416
US11078227 BB	20210803	US20180207870	20181203
US11174481 BB	20211116	US20190380695	20190410
US2016272970 AA	20160922	US20160066106	20160310
US2016272971 AA	20160922	US20160071395	20160316
US2016272978 AA	20160922	US20160071634	20160316
US2016347793 AA	20161201	US20160166323	20160527
US2016348107 AA	20161201	US20160166311	20160527
US2017096665 AA	20170406	US20160281309	20160930
US2018023084 AA	20180125	US20170716809	20170927
US2018023086 AA	20180125	US20170715765	20170926
US2018064819 AA	20180308	US20170452324	20170307
US2018195070 AA	20180712	US20180901810	20180221
US2018230470 AA	20180816	US20180954316	20180416
US2018258138 AA	20180913	US20180990415	20180525
US2019085012 AA	20190321	US20180207870	20181203
US2019256849 AA	20190822	US20190380695	20190410
US2019359984 AA	20191128	US20190429501	20190603
US2020263179 AA	20200820	US20200867925	20200506
US2021180066 AA	20210617	US20210179605	20210219
US2022033817 AA	20220203	US20210351169	20210617
US2022119439 AA	20220421	US20210363983	20210630
US9803201 BB	20171031	US20160071395	20160316
US9803205 BB	20171031	US20160071634	20160316
US9932586 BB	20180403	US20160281309	20160930
US9976141 BB	20180522	US20160166311	20160527
UY36926 A1	20170428	UY20160036926	20160930
UY37145 A1	20190830	UY20170037145	20170307
WO16149020 A1	20160922	WO2016US21677	20160310
WO16149313 A1	20160922	WO2016US22560	20160316
WO16149331 A2	20160922	WO2016US22591	20160316
WO16196239 A1	20161208	WO2016US34512	20160527
WO16196243 A1	20161208	WO2016US34517	20160527
WO17059223 A2	20170406	WO2016US54729	20160930
WO17059223 A3	20170511	WO2016US54729	20160930
WO17059223 A9	20170817	WO2016US54729	20160930
WO17214112 A1	20171214	WO2017US36108	20170606
WO18044350 A1	20180308	WO2017US21147	20170307
ZA201707148 A	20190227	ZA20170007148	20160527
ZA201707149 A	20190227	ZA20170007149	20160527

Priority Numbers: US20150168244P [20150529]; US20150235816P [20151001]; US20160383221P [20160902]; US20150134186P [20150317]; WO2016US22591 [20160316]; WO2016US34512 [20160527]; US20150235833P [20151001]; WO2016US34517 [20160527]; US20160346304P [20160606]; WO2016US54729 [20160930]; WO2017US36108 [20170606]; US20170456339P [20170208]; WO2017US21147 [20170307]; AU20170279512 [20170606]; AU20210266265 [20211110]; AU20160270593 [20160527]; AU20220200865 [20220210]; AU20160233364 [20160316]; AU20220203170 [20220512]; US20150235860P [20151001]; WO2016US22560 [20160316]; CN201680027422 [20160316]; CN201680031412 [20160527];

CN201780034726 [20170606]; EP20160765618 [20160316]; EP20160804090 [20160527]; EP20160852695 [20160930]; JP20170549311T [20160316]; JP20200148172 [20200903]; JP20180516738T [20160930]; JP20210039949 [20210312]; JP20180513740T [20160527]; JP20180513740 [20160527]; JP20210151282 [20210916]; JP20180555750T [20170307]; JP20210196293 [20211202]; JP20190516096T [20170606]; JP20220022652 [20220217]; JP20210039949 [20160930]; KR20197004205 [20170307]; KR20187034959 [20170606]; US20160066106 [20160310]; US20160166323 [20160527]; US20170716809 [20170927]; US20160071395 [20160316]; US20170452324 [20170307]; US20160071634 [20160316]; US20170715765 [20170926]; US20160281309 [20160930]; US20180901810 [20180221]; US20190429501 [20190603]; US20160166311 [20160527]; US20180954316 [20180416]; US20180207870 [20181203]; US20190380695 [20190410]; US20180990415 [20180525]; US20200867925 [20200506]; US20210179605 [20210219]; US20210351169 [20210617]; US20210363983 [20210630]

Probable Patent Assignee: ARROWHEAD PHARMACEUTICALS INC

Assignees: ARROWHEAD PHARMACEUTICALS INC; ARROWHEAD RES CORP; ARROWHEAD PHARMACY CO LTD; ARROWHEAD MADISON INC

Non Std Assignees: WAKEFIELD DARREN H; KANNER STEVEN B; LEWIS DAVID L; ALMEIDA LAUREN J; CHEN WEIJUN; BENSON JONATHAN D; ALMEIDA AARON; BLOKHIN ANDREI V; WOODS JUSTIN; WONG SO; CARLSON JEFFREY C; ROZEMA DAVID B; NICHOLAS ANTHONY L; MELQUIST STACEY; KANNER STEVEN; TRUBETSKOY VLADIMIR S; PEI TAO; LI ZHEN; GLEBOCKA AGNIESZKA; LAWLER MICHAEL; FLEITZ FRED; ALTENHOFER ERICH; KUMAR PANKAJ; ARROWHEAD RESEARCH CORP; ARROWHEAD PHARMACY CO

Inventors: ANDREI V BLOKHIN; JEFFREY C CARLSON; STACEY MELQUIST; DAVID L LEWIS; LAUREN J ALMEIDA; DAVID B ROZEMA; VLADIMIR S TRUBETSKOY; AARON ALMEIDA; ZHEN LI; DARREN H WAKEFIELD; STEVEN KANNER; TAO PEI; PEI TAO; LI ZHEN; KUMAR PANKAJ; GLEBOCKA AGNIESKA; LAWLER MICHAEL; ALTENHOFER ERICH; FLEITZ FRED; MELQUIST STACEY; KANNER STEVEN; ROZEMA DAVID B; LEWIS DAVID L; ALMEIDA LAUREN J; WAKEFIELD DARREN H; TRUBETSKOY VLADIMIR S; ALMEIDA AARON; KANNER STEVEN B; CHEN WEIJUN; BENSON JONATHAN D; BLOKHIN ANDREI V; WOODS JUSTIN; WONG SO; CARLSON JEFFREY C; NICHOLAS ANTHONY L; GLEBOCKA AGNIESZKA; SO WONG; WEIJUN CHEN; ANTHONY L NICHOLAS; STEVEN B KANNER; JONATHAN D BENSON; JUSTIN WOODS; AGNIESZKA GLEBOCKA; MICHAEL LAWLER; FRED FLEITZ; ERICH ALTENHOFER; PANKAJ KUMAR; ALMEIDA LAUREN; WANG SHAOMENG; CHEN WANSHI; WOODS JAMES; LI LI; LAWLER MATTHEW; WAKEFIELD DARREN; ROZEMA DAVID; LEWIS DAVID; TRUBETSKOY VLADIMIR; CHENG WEIJUN; LI CHEN; ZHEN LI OF; WEIJUN CHENG

Non Std Inventors: BLOKHIN ANDREI; BENSON JONATHAN; CARLSON JEFFREY; B DAVID ROZEMA; L DAVID LEWIS; J LAUREN ALMEIDA; H DARREN WAKEFIELD; S VLADIMIR TRUBETSKOY; B ROZEMA, DAVID B.; H WAKEFIELD, DARREN H.; L LEWIS, DAVID L.; J ALMEIDA, LAUREN J.

Agent(s): PIZZEYS PATENT AND TRADE MARK ATTORNEYS PTY LTD; DAVIES COLLISON CAVE PTY LTD; SHELSTON IP PTY LTD; SPRUSON AND FERGUSON; GOUDREAU GAGE DUBUC; LAVERY DE BILLY LLP; GOWLING WLG CANADA LLP; JOHANSSON AND LANGLOIS; VAN KOOIJ ADRIAAN; GRUENECKER PATENT U RECHTSANWAELTE PARTG MBB; MARIA ISABEL LEHMANN NOVO; UNITALEN ATTORNEYS AT LAW LTD; CHAN TANG AND KWOK; HNC INNOVATION LTD; MAROLITA SETIATI; SANFORD TCOLB AND CO; WOLFF BREGMAN AND GOLLER; AOKI ATSUSHI; EUGENIO PEREZ PEREZ; FRANCISCO JAVIER UHTHOFF ORIVE; CYNTHIA MADRIGAL DOMINGUEZ; DAVIES COLLISON CAVE ASIA PTE LTD; SPRUSON AND FERGUSON ASIA PTE LTD; MARKS AND CLERK SINGAPORE LLP; TOLGA CAYLAK; ROBERT MICHAEL; TEIGEN ROBERT MICHAEL; FISH AND RICHARDSON PC; FISH AND RICHARDSON PC; TEIGEN ROBERT M; VANDERVELDE PAUL; BARNES AND THORNBURG LLP; BARNES AND THORNBURG LLP; HONIGMAN LLP; HONIGMAN LLP; O BRIEN JONATHAN P; WEBER ANDREW N; AMGEN INC; ANGELA L; EKENA KIRK; ARROWHEAD MADISON INC; PURCELL ANGELA L; AMGEN INC

Designated States: AL; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR; BA; ME; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; IR; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LY; MA; MD; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PA; PE; PG; PH; QA; RU; RW; SA; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW; DJ; KW; KH

2. Family 74335928 (US2021123048 AA)


[View in PatBase](#)

Title
[EN] NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF LPA IN A CELL

Abstract
[EN] The present invention relates to products and compositions and their uses. In particular the invention relates to nucleic acid products that interfere with the LPA gene expression or inhibit its expression for use as treatment, prevention or reduction of risk of suffering cardiovascular disease such as coronary heart disease or aortic stenosis or stroke or any other disorder, pathology or syndrome linked to elevated of Lp(a)-containing particles.

International Class: A61K31/713; A61P9/00; C12N15/113; A61K31/7048; A61K47/26; A61K8/49; A61K31/7105; A61K47/54; A61P7/02; A61P9/10; A61K31/712; A61K31/7125; A61P3/06; A61K31/7084; C07H21/02; C07H21/04

Cooperative Patent Class: A61K31/713; A61K47/549; A61P9/00; C12N15/113; C12N15/1137; C12N2310/14; C12N2310/315; C12N2310/321; C12N2310/322; C12N2310/344; C12N2310/351; A61K31/7084; C12N2310/11; C12N2310/32; C12N2310/3515; C12N2310/53; C12N2310/532; C12N2320/30



Family Information

Patent Number	Publication Date	Application Number	Application Date
AU2018363840 AA	20200416	AU20180363840	20181113
AU2018363840 BB	20220929	AU20180363840	20181113
AU2019380628 AA	20210520	AU20190380628	20191113
BR112020009152 A2	20201027	BR20201109152	20181113
BR112021009213 A2	20210810	BR20211109213	20191113
CA3081905 AA	20200506	CA20183081905	20181113
CA3119239 AA	20210507	CA20193119239	20191113
CL2021001225 A1	20211224	CL20210001225	20210510
CN111465694 A	20200728	CN201880073189	20181113
CN113227372 A	20210806	CN201980074785	20191113
CO20210007372 A2	20210709	CO20210007372	20210604
CR20210301 A	20210916	CR20210000301	20191113
EA202190895 A1	20210810	EA20210090895	20191113
EP3483270 A1	20190515	EP20170201449	20171113
EP3483271 A2	20190515	EP20180179175	20180621
EP3483271 A3	20190710	EP20180179175	20180621
EP3710586 A1	20200923	EP20180803644	20181113
EP3880818 A1	20210922	EP20190801033	20191113
EP3880818 B1	20220928	EP20190801033	20191113
HK40031790 A1	20210312	HK20206022225	20201216
HK40035007 A1	20210507	HK20216024384	20210127
HK40048564 A1	20211203	HK20216038737	20210913
HK40057735 A1	20220414	HK20226047157	20220127
IL274503 AA	20200630	IL20180274503	20181113
IL283159 AA	20210630	IL20210283159	20210512
IN202027024540 A	20201002	IN202027024540	20200611
IN202127025259 A	20210820	IN202127025259	20210607
JP2021502120 T2	20210128	JP20200544151T	20181113
JP2022507282 T2	20220118	JP20210525771T	20191113
KR20200088392 A	20200722	KR20207016884	20181113
KR20210095878 A	20210803	KR20217017471	20191113
MX2020004897 A1	20201124	MX20200004897	20181113
MX2021005590 A1	20210920	MX20210005590	20191113

Patent Number	Publication Date	Application Number	Application Date
PE20211282 A1	20210719	PE20210000650	20191113
PH2021550801 A	20211004	PH20210550801	20210412
SG11202003230U A1	20200528	SG20201103230	20181113
SG11202103882Q A1	20210528	SG20211103882	20191113
US11319537 BB	20220503	US20200763458	20181113
US2021123048 AA	20210429	US20200763458	20181113
US2022002722 AA	20220106	US20210293303	20191113
US2022170016 AA	20220602	US20210559479	20211222
US2022290144 AA	20220915	US20220697405	20220317
WO19092283 A1	20190516	WO2018EP81106	20181113
WO20099476 A1	20200522	WO2019EP81158	20191113

Priority Numbers: EP20170201449 [20171113]; EP20180179175 [20180621]; GB20180015915 [20180928]; WO2018EP81106 [20181113]; EP20190174466 [20190514]; WO2019EP81158 [20191113]; US20210293303 [20210512]; US20210559479 [20211222]; US20200763458 [20200512]; US20220697405 [20220317]

Probable Patent Assignee: SILENCE THERAPEUTICS GMBH

Assignees: SILENCE THERAPEUTICS GMBH

Non Std Assignees: DAMES SIBYLLE; SCHUBERT STEFFEN; TENBAUM STEPHAN; FRAUENDORF CHRISTIAN; BETHGE LUCAS; HAUPTMANN JUDITH; WEINGARTNER ADRIEN; RIDER DAVID ANTHONY; WEINGAERTNER ADRIEN; ROBERT ROESSLE STRASSE 10

Inventors: RIDER DAVID ANTHONY; HAUPTMANN JUDITH; SCHUBERT STEFFEN; TENBAUM STEPHAN; WEINGAERTNER ADRIEN; DAMES SIBYLLE; FRAUENDORF CHRISTIAN; BETHGE LUCAS; SIBYLLE DAMES; STEFFEN SCHUBERT; STEPHAN TENBAUM; CHRISTIAN FRAUENDORF; LUCAS BETHGE; JUDITH HAUPTMANN; ADRIEN WEINGAERTNER; DAVID ANTHONY RIDER; WEINGARTNER ADRIEN; WEINGAERTNER ADRIEN; FLAUPTMANN JUDITH

Non Std Inventors: SIBYLLE DAMES S; STEFFEN SCHUBERT S; STEPHAN TENBAUM S; CHRISTIAN FRAUENDORF C; LUCAS BETHGE L; JUDITH HAUPTMANN J; ADRIEN WEINGAERTNER A; DAVID ANTHONY RIDER D A

Agent(s): WRAYS PTY LTD; BERESKIN AND PARR LLP SENCRL SRL; ESTUDIO CAREY LTDA; STEPHEN ROBERT JOHN; CMS CAMERON MCKENNA NABARRO OLSWANG LLP; CMS CAMERON MCKENNA NABARRO OLSWANG LLP; MEWBURN ELLIS LLP; SANYOU INTELLECTUAL PROPERTY LTD; HONG KONG KING AND SUN INTELLIGENCE CONSULTANCY LTD; HONGKONG TRUER IP LTD; 38 44 D AGUILAR STREET CENTRAL; HONG KONG; KORAKH AND CO; JORGE MIER Y CONCHA SEGURA; MARSHALL GERSTEIN AND BORUN LLP; MARSHALL GERSTEIN AND BORUN LLP


Designated States: AL; AT; BA; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; ME; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DJ; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; IR; JO; JP; KE; KG; KH; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LY; MA; MD; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PA; PE; PG; PH; QA; RU; RW; SA; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW

3. Family 92240280 (CN114703184 A)

[View in PatBase](#)

Title
[EN] LPA INHIBITORS AND USES THEREOF

Abstract
[EN] The invention relates to an RNA inhibitor for inhibiting LPA gene expression or a pharmaceutically acceptable salt thereof, the RNA inhibitor comprises a complementary region of an antisense strand, the complementary region comprises at least 12 consecutive nucleotides, and the antisense strand comprises the following nucleotide sequences: any one of SEQ ID NO.414-418 or a sequence which is not more than 3 nucleotides different from the SEQ ID NO.414-418. The RNA inhibitor directly degrades LPA mRNA, continuously and efficiently inhibits LPA gene expression, and can be used for treating or/and preventing LPA gene-mediated related cardiovascular and cerebrovascular diseases.



International Class: A61K31/713; A61P1/16; A61P29/00; A61P3/00; A61P3/06; A61P7/02; A61P9/10; C12N15/113
Cooperative Patent Class: A61K31/713; A61P1/16; A61P29/00; A61P3/00; A61P3/06; A61P7/02; A61P9/10; C12N15/113; C12N2310/14; C12N2310/315; C12N2310/321; C12N2310/322

Family Information

Patent Number	Publication Date	Application Number	Application Date
CN114703184 A	20220705	CN202210241706	20220311

Priority Numbers: CN202210241706 [20220311]
Probable Patent Assignee: XIAMEN GAMBOLI BIOMEDICAL CO LTD
Assignees: KYLONOVA XIAMEN BIOPHARMA CO LTD
Non Std Assignees: KYLONOVA XIAMEN BIOPHARMA CO; XIAMEN GAMBOLI BIOMEDICAL CO LTD
Inventors: CUI KUNYUAN; LU XUEQIN; MU ZHUO

4. Family 91055740 (WO22079221 A1)

[View in PatBase](#)

Title


[EN] RNA COMPOSITIONS AND METHODS FOR INHIBITING LIPOPROTEIN(A)

Abstract

[EN] The present disclosure relates to dsRNAs targeting LPA mRNA and modulating Lp(a) plasma levels, and methods of treating one or more conditions associated with LPA gene expression.

International Class: A61K31/713; A61P3/06; A61P9/10; C07H21/00; C12N15/113

Cooperative Patent Class: C12N15/113; C12N2310/14; C12N2310/315; C12N2310/317; C12N2310/323; C12N2310/33; C12N2310/351



Family Information

Patent Number	Publication Date	Application Number	Application Date
WO22079221 A1	20220421	WO2021EP78569	20211015

Priority Numbers: EP20200306222 [20201016]

Probable Patent Assignee: SANOFI SA

Assignees: SANOFI SA

Non Std Assignees: SANOFI

Inventors: BRUNNER BODO; FROTTIER BERTRAND; GUILLOT ETIENNE; HELMS MIKE; HOFMEISTER ARMIN; JAHN HOFMANN KERSTIN; SCHEIDLER SABINE

Agent(s): CABINET NONY

Designated States: AE; AG; AL; AM; AO; AT; AU; AZ; BA; BB; BE; BF; BG; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CH; CI; CL; CM; CN; CO; CR; CU; CY; CZ; DE; DJ; DK; DM; DO; DZ; EC; EE; EG; ES; FI; FR; GA; GB; GD; GE; GH; GM; GN; GQ; GR; GT; GW; HN; HR; HU; ID; IE; IL; IN; IR; IS; IT; JO; JP; KE; KG; KH; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LT; LU; LV; LY; MA; MC; MD; ME; MG; MK; ML; MN; MR; MT; MW; MX; MY; MZ; NA; NE; NG; NI; NL; NO; NZ; OM; PA; PE; PG; PH; PL; PT; QA; RO; RS; RU; RW; SA; SC; SD; SE; SG; SI; SK; SL; SM; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; WS; ZA; ZM; ZW

5. Family 91369585 (WO22098841 A1)


[View in PatBase](#)

Title

[EN] METHODS FOR TREATING ATHEROSCLEROTIC CARDIOVASCULAR DISEASE WITH LPA-TARGETED RNAI CONSTRUCTS

Abstract

[EN] The present invention relates to methods for treating or preventing atherosclerotic cardiovascular disease and other conditions associated with elevated levels of lipoprotein (a) (Lp(a)) using RNAi constructs targeting the LPA gene, which encodes apolipoprotein(a), a component of Lp(a) particles. In particular, the present invention relates to methods for reducing serum Lp(a) levels and reducing the risk of cardiovascular events in patients with elevated levels of Lp(a) comprising administering an LPA-targeted RNAi construct according to specific dosage regimens. Pharmaceutical compositions comprising the LPA-targeted RNAi constructs for use in the methods are also disclosed.



International Class: A61K31/713; A61P3/06; A61P9/00; A61P9/10; C12N15/113

Cooperative Patent Class: A61K31/7135; A61P3/06; C12N15/1137; C12N2310/14; C12N2310/315; C12N2310/317; C12N2310/343; C12N2310/346; C12N2310/351; C12N2320/35; C12Y304/21007

Family Information

Patent Number	Publication Date	Application Number	Application Date
TW202233837 A	20220901	TW20210141087	20211104
WO22098841 A1	20220512	WO2021US58012	20211104

Priority Numbers: US20200110309P [20201105]

Probable Patent Assignee: AMGEN INC

Assignees: AMGEN INC

Inventors: SOHN WINNIE; JONES ZACHARY; KASSAHUN HELINA

Agent(s): PURCELL ANGELA L

Designated States: AE; AG; AL; AM; AO; AT; AU; AZ; BA; BB; BE; BF; BG; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CH; CI; CL; CM; CN; CO; CR; CU; CY; CZ; DE; DJ; DK; DM; DO; DZ; EC; EE; EG; ES; FI; FR; GA; GB; GD; GE; GH; GM; GN; GQ; GR; GT; GW; HN; HR; HU; ID; IE; IL; IN; IR; IS; IT; JO; JP; KE; KG; KH; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LT; LU; LV; LY; MA; MC; MD; ME; MG; MK; ML; MN; MR; MT; MW; MX; MY; MZ; NA; NE; NG; NI; NL; NO; NZ; OM; PA; PE; PG; PH; PL; PT; QA; RO; RS; RU; RW; SA; SC; SD; SE; SG; SI; SK; SL; SM; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; WS; ZA; ZM; ZW

6. Family 85489720 (WO21119034 A1)

[View in PatBase](#)

Title


[EN] RNAI CONSTRUCTS AND METHODS FOR INHIBITING LPA EXPRESSION

Abstract

[EN] The present invention relates to RNAi constructs for reducing expression of the LPA gene, which encodes apolipoprotein(a), a component of lipoprotein(a) (Lp(a)) particles. Methods of using such RNAi constructs to treat or prevent cardiovascular disease, such as coronary artery disease, peripheral artery disease, stroke, and myocardial infarction, and to reduce serum Lp(a) levels are also described.

International Class: A61K47/54; C12N15/113; C12N15/63

Cooperative Patent Class: A61K47/549; C12N15/1137; C12N2310/14; C12N2310/315; C12N2310/343; C12N2310/346; C12N2320/32



Family Information

Patent Number	Publication Date	Application Number	Application Date
AU2020399636 AA	20220602	AU20200399636	20201208
CA3163322 AA	20220527	CA20203163322	20201208
EP4073252 A1	20221019	EP20200838702	20201208
MX2022007005 A1	20220909	MX20220007005	20201208
WO21119034 A1	20210617	WO2020US63844	20201208

Priority Numbers: US20190945777P [20191209]; WO2020US63844 [20201208]

Probable Patent Assignee: AMGEN INC

Assignees: AMGEN INC

Non Std Assignees: WU BIN; OLLMANN MICHAEL; HOMANN OLIVER; CHENG YUAN

Inventors: OLLMANN MICHAEL; CHENG YUAN; HOMANN OLIVER; WU BIN

Non Std Inventors: BIN WU; MICHAEL OLLMANN; OLIVER HOMANN; YUAN CHENG

Agent(s): SPRUSON AND FERGUSON; SMART AND BIGGAR LLP; LAU SARAH JANE; KILBURN AND STRODE LLP; MARIA ANGELICA PARDAVELL JUAREZ; PURCELL ANGELA L

Designated States: AL; AT; BA; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; ME; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DJ; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; IR; JO; JP; KE; KG; KH; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LY; MA; MD; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PA; PE; PG; PH; QA; RU; RW; SA; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; WS; ZA; ZM; ZW


[View in PatBase](#)

[EN] METHODS AND COMPOSITIONS FOR MODULATING RHO-MEDIATED GENE TRANSCRIPTION

[EN] The present invention is directed to methods and compositions methods and compositions for determining and inhibiting gene transcription in mammalian cells. The invention relates to novel inhibitors of rho-mediated gene transcription and to compounds that may be used as therapeutic agents.

Cooperative Patent Class: A61K31/165

US Class: 435/375; 514/603; 514/616; 564/155; 564/86



Patent Number	Publication Date	Application Number	Application Date
<u>US2009264533 AA</u>	20091022	US20060910383	20060321
<u>WO06104751 A2</u>	20061005	WO2006US10089	20060321
<u>WO06104751 A3</u>	20070118	WO2006US10089	20060321

Agent(s): MARSHALL GERSTEIN AND BORUN LLP

Designated States: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BE; BF; BG; BJ; BR; BW; BY; BZ; CA; CF; CG; CH; CI; CM; CN; CO; CR; CU; CY; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; FR; GA; GB; GD; GE; GH; GM; GN; GQ; GR; GW; HR; HU; ID; IE; IL; IN; IS; IT; JP; KE; KG; KM; KN; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; LY; MA; MC; MD; MG; MK; ML; MN; MR; MW; MX; MZ; NA; NE; NG; NI; NL; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SI; SK; SL; SM; SN; SY; SZ; TD; TG; TJ; TM; TN; TR; TT; TZ; UA; UG; US; VC; VN; YU; ZA; ZM; ZW

8. Family 91596843 (WO22106658 A1)

[View in PatBase](#)

Title

[EN] MASS SPECTROMETRY SYSTEM AND METHOD FOR PROVIDING AN INDICATION OF INTEGRITY OF A BIOLOGICAL SAMPLE

Abstract

[EN] A mass spectrometry system comprises a mass spectrometry apparatus configured to provide mass spectrometry data of a biological sample; and a computer system configured to process the mass spectrometry data to determine a characteristic of the biological sample as integrity data of the biological sample; and output an indication of the similarity to a predetermined sample characteristic as integrity data of the biological sample. A computerized method provides an indication of integrity of a biological sample from mass spectrometry data, the computerized method comprising: processing mass spectrometry data of a biological sample to determine a sample characteristic of the biological sample; and outputting an indication of the similarity to a predetermined sample characteristic as integrity data of the biological sample.

International Class: G16B40/10

Cooperative Patent Class: G16B40/10

Family Information

Patent Number	Publication Date	Application Number	Application Date
EP4002375 A1	20220525	EP20200208936	20201120
WO22106658 A1	20220527	WO2021EP82375	20211119

Priority Numbers: EP20200208936 [20201120]


Probable Patent Assignee: OMICERA DIAGNOSTICS GMBH

Assignees: OMICERA DIAGNOSTICS GMBH

Inventors: GEYER PHILIPP EMANUEL; WINTER SEBASTIAN VIRREIRA; STRAUSS MAXIMILIAN THOMAS; DOLL SOPHIA

Agent(s): SACKIN ROBERT; REDDIE AND GROSE LLP; FRANK ALEXANDER; REDDIE AND GROSE LLP

Designated States: AL; AT; BA; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; ME; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DJ; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; IR; JO; JP; KE; KG; KH; KM; KN; KP; KR; KW; KZ; LA; LC; LK; LR; LS; LY; MA; MD; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PA; PE; PG; PH; QA; RU; RW; SA; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; WS; ZA; ZM; ZW



9. Family 54993769 (US2015057298 AA)

[View in PatBase](#)

Title
[EN] NOVEL COMPOUNDS

Abstract
[EN] The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, X, m, R2, Y, R3, Z, n, R4, A and B are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.


International Class: A61K31/192; A61P29/00; A61P9/10; C07C235/52; A61K31/44; A61K31/505; C07D213/81; C07D239/34; A61P35/00; A61K; A61P; C07C; C07D; A61K31/195; A61K31/277; A61K31/513; A61K45/00; A61P25/04; A61P43/00; C07C231/12; C07C253/30; C07C255/54; A61K31/166; C07C235/46; C07D213/78; C07C235/44; C07C233/81; C07C233/87; C07C235/40; C07C235/64

Cooperative Patent Class: A61K31/195; A61K31/277; A61K31/44; A61K31/505; A61P25/04; A61P29/00; A61P43/00; A61P9/10; C07C235/44; C07C235/46; C07C235/52; C07C255/54; C07C2601/02; C07C2601/04; C07D213/78; C07D213/81; C07D239/34; A61K31/166; A61K31/192

US Class: 1/1; 514/256; 514/269; 514/350; 514/563; 544/298; 546/298; 562/451

Family Information

Patent Number	Publication Date	Application Number	Application Date
AR097403 AA	20160309	AR2014P103129	20140820
AU2014310404 AA	20160310	AU20140310404	20140820
AU2014310404 BB	20180712	AU20140310404	20140820
BR112016003465 A2	20170801	BR20161103465	20140820
CA2921742 AA	20160218	CA20142921742	20140820
CL2016000387 A1	20161216	CL20160000387	20160219
CN105473548 A	20160406	CN201480046178	20140820
CN105473548 B	20180323	CN201480046178	20140820
CO7590632 A2	20160429	CO20160025604	20160204
CR20160084 A	20160527	CR20160000084	20160219
EA028818 B1	20180131	EA20160090390	20140820
EA201690390 A1	20160831	EA20160090390	20140820
EP3036215 A1	20160629	EP20140756117	20140820
GB201314926 A0	20131002	GB20130014926	20130820
HK1225712 A1	20170915	HK20160113982	20161208
ID201712875 A	20171130	ID2016P0001756	20140820
IL243780 A0	20160421	IL20140243780	20140820
IN201617004918 A	20160805	IN201617004918	20160211
JP2016528274 T2	20160915	JP20160535530T	20140820
JP6422974 B2	20181114	JP20160535530T	20140820
KR20160045797 A	20160427	KR20167007214	20140820
MA38854 A1	20170731	MA20140038854	20140820
MA38854 B1	20180531	MA20140038854	20140820
MX2016001896 A1	20160526	MX20160001896	20140820
PE02842016 A1	20160427	PE20160000269	20140820
PE20160284 A1	20160427	PE20160000269	20140820
PH2016500322 A	20160502	PH20160500322	20160218
SG11201601250T A1	20160330	SG20161101250	20140820
TH165167 A	20170720	TH20161000893	20140820
TN2016000061 A1	20170705	TN20160000061	20140820
TW201536722 A	20151001	TW20140128316	20140818
US10100018 BB	20181016	US20140913135	20140820



Patent Number	Publication Date	Application Number	Application Date
US2015057298 AA	20150226	US20140463780	20140820
US2016207880 AA	20160721	US20140913135	20140820
US2019010129 AA	20190110	US20180999570	20180820
US9464060 BB	20161011	US20140463780	20140820
UY35708 A1	20141231	UY20140035708	20140819
WO15025164 A1	20150226	WO2014GB52558	20140820
ZA201600753 A	20190731	ZA20160000753	20160203

Priority Numbers: GB20130014926 [20130820]; WO2014GB52558 [20140820]; US20160913135 [20160219]; US20180999570 [20180820]

Probable Patent Assignee: TAKEDA PHARMACEUTICAL CO LTD

Assignees: TAKEDA PHARMACEUTICAL CO LTD; TAKEDA PHARMACEUTICALS CO; TAKEDA PHARMACEUTICAL; TAKEDA CAMBRIDGE LTD

Non Std Assignees: PARMAR ALKA; MACK STEPHEN; DAVENPORT RICHARD; WRIGHT SUSANNE; CANNING HANNAH; BUFFHAM WILLIAM; FARNABY WILLIAM

Inventors: PARMAR ALKA; MACK STEPHEN; DAVENPORT RICHARD; WRIGHT SUSANNE; CANNING HANNAH; FARNABY WILLIAM; BUFFHAM WILLIAM; WILLIAM BUFFHAM; HANNAH CANNING; RICHARD DAVENPORT; WILLIAM FARNABY; STEPHEN MACK; ALKA PARMAR; SUSANNE WRIGHT

Agent(s): PHILLIPS ORMONDE FITZPATRICK; BERESKIN AND PARR LLP SENCRL SRL; CLARO SWINBURN LUIS FELIPE; MARGARITA CASTELLANOS ABONDANO; JONES NICHOLAS ANDREW; WITHERS AND ROGERS LLP; REED SMITH RICHARDS BUTLER; DORA AM BADAR S PSI AM BADAR AND PARTNERS; TAKASHIMA HAJIME; FRANCISCO JAVIER UHTHOFF ORIVE; FINNEGAN HENDERSON FARABOW GARRETT AND DUNNER LLP; FINNEGAN HENDERSON FARABOW GARRETT AND DUNNER LLP

Designated States: AL; AT; BA; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; ME; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR; AE; AG; AM; AO; AU; AZ; BB; BF; BH; BJ; BN; BR; BW; BY; BZ; CA; CF; CG; CI; CL; CM; CN; CO; CR; CU; DM; DO; DZ; EC; EG; GA; GD; GE; GH; GM; GN; GQ; GT; GW; HN; ID; IL; IN; IR; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LY; MA; MD; MG; ML; MN; MR; MW; MX; MY; MZ; NA; NE; NG; NI; NZ; OM; PA; PE; PG; PH; QA; RU; RW; SA; SC; SD; SG; SL; SN; ST; SV; SY; SZ; TD; TG; TH; TJ; TM; TN; TT; TZ; UA; UG; US; UZ; VC; VN; ZA; ZM; ZW